In sum, these integrated analyses with clinical data support the future use of CmPn members’ expression data, along with AFP, as potential prognostic biomarkers for distinguishing between primary subtypes of liver cancer and evaluating tumor recurrence in patients. The gene discussed is AFP; the disease is liver cancer.